Alzheimer’s drug failure sends Lundbeck’s shares crashing

04:53 EDT 23 Sep 2016 | Pharmafile

Lundbeck’s experimental idalopirdine has failed to meet its primary endpoint in its first Phase III trial in the treatment of Alzheimer’s.

The company saw its shares fall by 17% as a result of the news, its biggest drop in four years. The study could not reproduce the promising findings of earlier studies, with the drug failing to improve symptoms of the disease according to the Alzheimer’s Disease Assessment Scale-cognitive (ADAS-cog).

read more

Original Article: Alzheimer’s drug failure sends Lundbeck’s shares crashing


More From BioPortfolio on "Alzheimer’s drug failure sends Lundbeck’s shares crashing"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...